CAS NO: | 2156-56-1 |
包装 | 价格(元) |
100mg | 电议 |
500mg | 电议 |
1 g | 电议 |
5 g | 电议 |
生物活性 | Sodium dichloroacetate is a metabolic regulator incancercells' mitochondria with anticancer activity. Sodium dichloroacetate inhibitsPDHK, resulting in decreased lactic acid in the tumor microenvironment. Sodium dichloroacetate increasesreactive oxygen species(ROS)generation and promotescancercellapoptosis. Sodium dichloroacetate also works asNKCCinhibitor[1]. | ||||||||||||||||
IC50& Target | PDHK; Reactive oxygen species (ROS); Apoptosis; NKCC[1] | ||||||||||||||||
体外研究 (In Vitro) | Sodium dichloroacetate increases ROS generation in mitochondria. Sodium dichloroacetate affects cell growth and viability through the ROS production increase derived from the promotion of oxidative metabolism. The effects of Sodium dichloroacetate on multiple myeloma cell viability, cell cycle arrest, and apoptotic cell death were associated with pyruvate dehydrogenase kinases (PDK) inhibition, restored pyruvate dehydrogenase (PDH) activity, and the promotion of oxidative metabolism in association with increased intracellular ROS production which depends on the Sodium dichloroacetate dose. The Sodium dichloroacetate effects cooperated with C I inhibition promoting the oxidative stress in rat VM-M3 glioblastoma cells. Increased ROS levels in Sodium dichloroacetate-treated cancer cells are related to the induction of apoptosis associated with the increased cytochrome c expression. Sodium dichloroacetate causes ROS-dependent T-cell differentiation[1]. | ||||||||||||||||
体内研究 (In Vivo) | The NKCC1 RNA expression levels in Sodium dichloroacetate-treated gonad-intact and castrated males are significantly decreased, and no such effect is determined in the gonad-intact and castrated female Sodium dichloroacetate-treated rats[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 150.92 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C2HCl2NaO2 | ||||||||||||||||
CAS 号 | 2156-56-1 | ||||||||||||||||
中文名称 | 二氯乙酸钠 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 100 mg/mL(662.60 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|